The BCS1L Knockout SK-HEP-1 Polyclonal Cells product provides a CRISPR/Cas9-edited polyclonal knockout cell population in which the BCS1L gene has been disrupted within the SK-HEP-1 human hepatic endothelial cell background. This polyclonal knockout pool, generated using CRISPR/Cas9 technology, enables loss-of-function studies of BCS1L in a liver-derived endothelial model system. The product is supplied as a heterogeneous population of edited cells, offering a powerful tool for investigating mitochondrial biology and its intersection with hepatocellular endothelial phenotypes without the need for single-cell cloning.
SK-HEP-1 cells, originally derived from a human liver adenocarcinoma, display an endothelial-like phenotype characterized by expression of endothelial markers and functional properties such as tube formation, angiogenic signaling, and barrier integrity. This cell line is widely utilized to model liver sinusoidal endothelial cell biology, including hepatic metabolism, drug metabolism, and endothelial barrier function. The adherent morphology and robust proliferation of SK-HEP-1 cells make them suitable for a broad range of functional assays and high-throughput screening platforms.
BCS1L encodes a mitochondrial AAA+ ATPase that functions as a chaperone essential for the incorporation of the Rieske iron-sulfur protein (UQCRFS1) into complex III of the respiratory chain. The protein interacts with assembly factors TTC19 and LYRM7 and collaborates with the TIM23 translocase complex to mediate UQCRFS1 insertion. Its activity is transcriptionally regulated by nuclear respiratory factor 1 (NRF1), peroxisome proliferator-activated receptor ?? coactivator 1?? (PPARGC1A), and estrogen-related receptor ?? (ESRRA). Downstream consequences of BCS1L-dependent complex III assembly encompass electron transport chain activity, ATP synthesis, reactive oxygen species (ROS) production, and apoptotic signaling through factors such as UQCRC1, UQCRC2, CYC1, and MT-CYB.
In SK-HEP-1 cells, BCS1L disruption profoundly alters mitochondrial respiration and energy homeostasis, generating a relevant model for hepatic endothelial dysfunction linked to mitochondrial complex III deficiency. Because these cells normally rely on oxidative phosphorylation to support angiogenic and metabolic activities, BCS1L loss is expected to drive metabolic reprogramming, elevated ROS, and activation of stress signaling pathways. This cellular context is particularly valuable for dissecting how mitochondrial defects contribute to hepatopathies, including GRACILE syndrome and Leigh syndrome-associated liver involvement.
Researchers can employ the BCS1L knockout SK-HEP-1 polyclonal cells in a variety of experimental workflows: assessing complex III assembly by blue native PAGE, measuring oxygen consumption and extracellular acidification via Seahorse respirometry, quantifying mitochondrial ROS with MitoSOX staining, confirming UQCRFS1 loss by western blot, detecting apoptosis by Annexin V, evaluating ATP levels, and examining cell migration. These assays support applications in mitochondrial disease modeling, hepatocellular metabolism investigations, drug screening for mitochondrial disorders, and the study of endothelial dysfunction in liver diseases. For further technical details, please contact Ascent Research.
